Its about psychology & technicals. If you look at the chart it was set up for a pullback. They move the stock down 3% on 100K shares which generates some selling & not much buying since its overbought & the markets weak. They buy back those shares & they've still created a 2 - 3% loss on the day. They do the same thing everyday until buyers step back in.
The stock would've been down 7 cents without the article & its up 3 cents now so that equals 10 cents. You've got to think out of the box.
I think our wrong even if you won't admit it.
Trade date controls
When determining what year you sold your stock, the trade date is what matters. This is the day the transaction took place on the stock exchange. If you contact your broker on the last trading day of the year, you can complete a sale in the current year if your broker executes the trade that day. On major exchanges, the last trading day is December 31 unless that day falls on a weekend.
Stock market trades generally settle a few days after the trade date. This is the day shares and cash actually change hands. But the settlement date doesn't matter for purposes of determining when your sale took place. If your trade date is in the current year and your settlement date is in the following year, the tax law says you made the sale in the current year (year of the trade date).
When funds unload they try to do it in a controlled manner until they have to dump whatever shares are still in their hands at the last minute. The time to buy maybe at the end of the day trading tomorrow.
Congats on CPRX. The rich keep getting richer. I wasn't home today or I would have placed a few dollars on the trade. I was able to unload my ECYT calls @ .90 that I bought for .65 or else I'd really be in a lousy mood.
The only way to turn this ship around is with news. Just because a stock is cheap doesn't mean it can't get cheaper when you've got a lot of shares in retail hands with short timeframes.
That's hilarious. If I cared about red thumbs then I'd never post but I got 12 green ones & one red which you probably gave.
I think I'm going to limit my own posts for awhile. Maybe you can pick up the slack & get the attention you seek.
Your like the BB's. You own everything. Nice call
On another topic: Did you see the note Canaccord had out on ACOR's purchase of CVTS. They estimated the market opportunity at $50 - $100 million a year instead of the $500 + market ACOR is using. Its hard to believe ACOR could be that wrong. Decreases my interest in CYNAF if their right.
For ALL NSCLC (adeno and squamous):
OS: 11.5 months for Vinta+DTX vs. 8.8 for DTX
Adeno subset : Vinta+DTX
OS: 12.5 months for Vinta+DTX vs. 6.6 for DTX
I think the company will say the OS numbers in the Adeno predefined subset warrants moving into Phase III once the full data set proves comparable. I'll actually be surprised if the stock doesn't have a nice move in the following days.
Dexcel actually holds 2 positions on the board. Ilan Oren is currently Vice President, Business Development at Dexcel Pharma.
Dexcel holds a position on the board of directors. Tomer Gold is the VP of R&D of Dexcel. I previously mentioned ACOR may have approached CYNAF & been turned away which lead them to Civitis.
I must be stupid for not investing in ESPR but I'll have to look for an entry now. I remember your email.
I'll pass on SAGE. I'm not sure I've ever seen a patient with a diagnosis of super-refractory status epilepticus.
Andre, I bought DRRX as another lotto play last week. Royalty agreement with PFE on a abuse deterrent Oxycodone that should file at the end of 2015. Their also developing a long acting bupivacaine which would compete against PCRX's (Exparel). Meeting with the FDA at any time to discuss what steps they need to take in order to gain approval after receiving a CRL. A number of other small products.
Number of potential catalysts could move it to higher levels.
Could someone remind me the last time the company reported a positive pipeline development that wasn't expected?
Ok, second question
What the heck is management doing to deserve their salaries?
Those are additional shares which dilute but its really not significant when your talking about a company with 900 million shares. You'll see a lot of companies buy back shares in order to offset the ever increasing share count from employee grants. The main thing is that the company is projecting growth of 4% & you get a 4.9% divy. Just sit back & don't worry about the daily manipulation.